TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Collection for Adult Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Age 18 or greater.~Normal renal function: creatinine less than1.5 mg/dL, proteinuria less than1+.~Normal liver function: bilirubin less than 2.5 mg/dL, ALT less than 2.5 times the upper limit of normal, all other transminases less than 2.5 times the upper limit of normal.~Normal blood counts: WBC 3,000-10,000/mm3, granulocytes greater than 1,500/mm3, platelets greater than 150,000/mm3, hemoglobin greater than 12.5g/dL, MCV within normal limits.~Female volunteers of childbearing age should have a negative serum pregnancy test within one week of beginning G-CSF administration.~Meets NIH Department of Transfusion Medicine (DTM) eligibility criteria for blood component donation for in vitro research use (negative serologic tests for syphilis, hepatitis B and C, HIV, and HTLV-1).~Ability to give informed consent to participate in the protocol.~EXCLUSION CRITERIA:~Any underlying hematologic disorder including sickle cell disease.~Active viral, bacterial, fungal, or parasitic infection.~History of autoimmune disease, such as rheumatoid arthritis or systemic lupus erythematosus.~History of cancer excluding squamous carcinoma of the skin and cervical carcinoma in situ.~History of cardiovascular disease or related symptoms such as chest pain or shortness of breath.~Any positive serum screening test as listed below.~Allergy to G-CSF or bacterial E. coli products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Eligible healthy volunteers 18 and older

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: NICU-TECH RM9L-RS Probe ME Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Neonates that are 23 gestational weeks at birth (and greater than 500 grams) to a 6 month old born infant at term (maximum weight 7 kg) who already have one or more lines placed (PIV/PAC/UVC/UACs/PICC) as part of their medical care. NO INFANT WILL HAVE A LINE PLACE FOR THE PURPOSE OF THIS STUDY~Exclusion Criteria:~* Neonates that are less than 23 gestational weeks at birth~* Neonates that are 23 gestational weeks at birth but are less than 500 grams in weight~* Patients weighing more than 7 kg.-Patients older than 6 months

- Gender: ALL
- Minimum Age: 23 Weeks
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Arm 1: observational ultrasound (Type: None): Collection of image data with the ultrasound probe.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic proof of adenocarcinoma of the colon or rectum with evidence of metastatic disease. The site of the primary lesion must be or have been confirmed endoscopically, radiologically, or surgically to be or have been in the large bowel~* Patients must have received one (and only one) prior chemotherapy regimen for metastatic disease using 5-FU/LV or Xeloda in combination with oxaliplatin and Avastin.~* \> 4 weeks must have elapsed from the time of major surgery~* \> 2 weeks must have elapsed from the time of minor surgery~* \> 4 weeks must have elapsed from the time of major radiotherapy~* Normal organ and marrow function~* Measurable disease be RECIST criteria~* Older than 18 years of age~* ECOG performance status of 0-1~* Life expectancy \> 12 weeks~Exclusion Criteria:~* Previous treatment with irinotecan, cetuximab or SU011248~* Any of the following within the 12 months prior to study drug administration: severe/unstable angina; myocardial infarction; symptomatic congestive heart failure; cerebrovascular accident; or transient ischemic attack.~* Known brain metastases or carcinomatous meningitis~* Uncontrolled serious medical or psychiatric illness~* NCI CTCAE grade 3 or greater hemorrhage within 4 weeks of starting study treatment~* Uncontrolled hypertension~* Diagnosis of any secondary malignancies with the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, localized prostate cancer with a normal PSA within the past 3 months, in situ bladder cancer, or in situ cervical cancer~* Pregnant or breastfeeding~* Concurrent treatment on another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heterozygote or homozygote of HLA-A\*02:01 allele~* Inoperable or recurrent pancreatic cancer with or without any prior therapy~* Difficult to continue the prior therapy due to treatment-related toxicities~* ECOG performance status 0-2~* Evaluable primary or metastatic lesion with RECIST v.1.0 criteria~* Clearance period from prior therapy more than 4 weeks~* Life expectancy more than 3 months~* Laboratory values as follows 2,000/μL\< WBC \<15,000/μL Platelet count \>100,000/μL AST \<150 IU/L ALT \<150 IU/L Total bilirubin \<3.0 mg/dl Serum creatinine \<3.0 mg/dl~Exclusion Criteria:~* Pregnancy (refusal or inability to use effective contraceptives)~* Breastfeeding~* Active or uncontrolled infection~* Systemic use of corticosteroids or immunosuppressants~* Uncontrollable brain metastasis and/or meningeal infiltration~* Unhealed external wound~* Possibilities of complicated paralytic ileus or interstitial pneumonitis~* Decision of not eligible determined by principal investigator or attending doctor

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Peptide vaccination (Type: EXPERIMENTAL): VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years;~* hospitalization in an Internal Medicine Unit and a Barbar score of 4 points or above~* Platelet count between 100,000/uL and 30,000/uL~* written informed consent~Exclusion Criteria:~* Active bleeding or bleeding within the previous 3 months;~* Known bleeding diathesis;~* Active gastroduodenal ulcer;~* Severe renal insufficiency defined by a creatinine clearance below 20 mL/min;~* Ongoing treatment with unfractionated heparin, low-moleculr-weight heparin, fondaparinux, or oral anticoagulants Trattamento in corso con eparina non~* Prophylaxis with unfractionated heparin, low-moleculr-weight heparin, or fondaparinux for more than 48 hours;~* double antiplatelet therapy or acetylsalicylic acid at daily doses above 165 mg;~* planned invasive procedure during the period of thromboprophylaxis;~* Hemoglobin values below 9 g/dL;~* AST or ALT above 2 times the uper limit of normal;~* pregnancy or breast feeding;~* life expectancy lower than 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fondaparinux (Type: EXPERIMENTAL): Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hemoglobin SC Disease With Hydroxyurea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of HbSC disease~2. Score equal or lower than 80 on the PedsQL™ Sickle Cell Disease Module version 3.0~3. Have experienced a sickle cell disease related complication~Exclusion Criteria:~1. Failure to meet inclusion criteria.~2. Hydroxyurea usage in the last 3 months.~3. Chronic RBC transfusion therapy.~4. Packed red blood cell transfusion in the last 3 months (temporary exclusion).~5. Pregnancy, or refusal to use medically effective birth control if female and sexually active.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxurea (Type: EXPERIMENTAL): Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 18 years or older in whom the diagnosis of X-ALD has been confirmed by VLCFA assay and/or mutation analysis.~* Clinical evidence of spinal cord involvement with EDSS score between 1 and 6.5. Patients with an EDSS score of 6.5 are severely affected but have retained the capacity to walk 20 meters with the aid of a walker, crutch, or two canes.~* Either a normal brain MRI, or a type 3 pattern of MRI abnormality in which the abnormality is considered to represent the centripetal extension of the distal axonopathy.~* Adrenal function assessed by measurement of plasma ACTH and appropriate steroid replacement if adrenal insufficiency is present.~Exclusion Criteria:~* Kurtzke EDSS score of \>6.5.~* Cognitive or behavioral abnormalities that impair capacity to give informed consent or carry out procedures that form part of the protocol.~* Current use, or use within 3 months, of Lorenzo's oil or other therapies that may alter the course of X-ALD. Bone marrow transplant will be a permanent exclusion criterion.~* Contraindications for MRI procedure such as subjects with paramagnetic materials in the body, such as aneurysm clips, pacemakers, intraocular metal or cochlear implants.~* Subjects who are pregnant.~* Allergies to peppermint~* Presence of non-specific conditions that may interfere with clinical assessment or participation in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All male patients \>=60 years old who undergo inpatient thoracic surgery for major resections.~Exclusion Criteria:~* - Prisoners~* Adults unable to consent~* End stage renal disease on hemodialysis~* Indwelling urinary catheter~* Child-Pugh class C hepatic failure~* Usage of the following medications prior to surgery: strong CYP 3A4 inhibitors, strong CYP2D6 inhibitors, other alpha-adrenergic blocking agents, PDE5 inhibitors, and cimetidine~* patients known to be CYP2D6 poor metabolizers~* History of prostatectomy or cystectomy~* Patients with contraindications to tamsulosin and those at high risk for side effects: hypersensitivity to tamsulosin HCl or any component of FLOMAX capsules, hypersensitivity to sulfonamides. History of known glaucoma, hypotension, plan to undergo cataract surgery in the next 2 weeks

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perioperative Tamsulosin Hydrochloride (Type: EXPERIMENTAL): Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.
- Historical Comparator (Type: NO_INTERVENTION): Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Near Infrared Spectroscopy in Patients Undergoing Robotic Assisted Laparoscopic Surgery in the Trendelenburg Position

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for robotic assisted laparoscopic surgery in a Trendelenburg position~Exclusion Criteria:~* Preexisting moderate neurological disease~* Moderate cerebrovascular disease~* Coronary disease with angina pectoris (CCS ≥ 1)~* Peripheral arterial disease II (with intermittent claudicatio)~* Cardiac insufficiency (NYHA \>2)~* Tumour in pharynx, larynx or oesophagus, an aneurysm of the thoracic aorta

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Prostatic Surgery (Type: None): Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
- Colorectal Surgery (Type: None): Patient scheduled for a robotic assisted laparoscopic colorectal surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: National Breast Cancer and Lymphedema Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer survivorship~Exclusion Criteria:~* Age \< 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast cancer survivors (Type: None): Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Guidant Microwave Ablation System for the Treatment of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient age \>= 18 years~* Documented permanent AF (for at least three months)~* Scheduled for an open chest cardiac surgery for the primary indication of mitral valve repair or replacement~* Has been informed of the nature of the study, agrees to its provisions, and provided written informed consent, which was approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site~Exclusion Criteria:~* Cerebral vascular accident (CVA, stroke) or transient ischemic attack (TIA) within the previous 6 months~* Myocardial infarction within the previous 6 weeks~* Documented history of pulmonary vein stenosis~* Previous ablation attempt for AF~* Previous thoracic procedures~* Left atrial size \> 7.0 cm~* Left ventricular ejection fraction \< 30%~* Presence of left atrial or left atrial appendage thrombi~* Esophageal fistula or other stricture, untreated esophagitis, varices, dysphagia or odynophagia contraindicating transesophageal echocardiography~* Known allergy or contraindication to warfarin therapy~* Known allergy or contraindication to antiarrhythmic (Classes IA, IC, III) therapy~* Other comorbidity with reduced life expectancy of less than 1 year or protocol noncompliance that would limit follow-up~* Geographically remote or unable to return for follow-up examinations~* Pregnant or planning to become pregnant during the study~* Enrolled in any concurrent study, without Guidant written approval, that may confound the results of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing cardiac surgery requiring cardiopulmonary bypass (CPB)~* Heparin resistant according to this definition: initial activated clotting time (ACT) after an intravenous loading dose of heparin (300 u/kg) is less than 480 seconds~Exclusion criteria:~* current use of one or more of these medications:~  * warfarin (within 3 days of surgery);~ * streptokinase;~ * tissue plasminogen activator;~ * abciximab,~ * eptifibatide,~ * tirofiban or~ * clopidogrel.~* known hypersensitivity to goat or goat milk proteins,~* patients with pre-existing coagulopathy defined as a history of bleeding or laboratory bleeding disorder (e.g., von Willebrand disease, platelet disorder) and~* patients receiving direct thrombin inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant antithrombin (rhAT) (Type: EXPERIMENTAL): Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Human Tear Proteins

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* able to cooperate with tear sample collection~* provide written informed consent~Exclusion Criteria:~* special populations (children, pregnant or lactating females, prisoners, etc)~* refusal to sign sudy consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study Subject (Type: None): Subjects receiving eye examination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-penetrating brain injury with post-resuscitation Glasgow Coma Score (GCS) \< 8 (motor 1-5)~2. Estimated or known age \> 16 and \< 45 years old~3. Time of Injury within 2.5hrs of arrival at hospital~Exclusion Criteria:~1. GCS = 7 or 8 with a normal head Cat Scan (CT) scan or showing only mild Subarachnoid hemorrhage (SAH)or skull fracture or GCS \> 9 post- randomization~2. GCS = 3 AND bilaterally non-reactive pupils~3. Abbreviated Injury Score (AIS) \> 4 for any body area except head~4. Positive abdominal ultrasound or CT scan~5. Persistent hypotension (systolic blood pressure \< 110mmHGg)~6. Persistent hypoxia (O2 Saturation \< 94%)~7. Positive pregnancy test~8. Injured greater than 2.5 hours from hospital arrival~9. Pre-existing medical conditions, if known

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- hypothermia (Type: ACTIVE_COMPARATOR): Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
- control (Type: NO_INTERVENTION): treated at normothermia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy